Clinical

In the first keynote session at the ACCC 2023 Annual Meeting and Cancer Center Business Summit, the history of CRISPR genome editing and its potential in cancer and other settings took center stage.

A panel of medical experts discuss diagnostic imaging surrounding DME and wet AMD.

Drs Coney, Luo, and Sheth discuss potential novel treatment mechanisms or options that we could see in the future with wet AMD and DME.

The extended follow-up results are consistent with the primary analysis of the CLEAR trial, supporting the increased efficacy of first-line lenvatinib plus pembrolizumab compared with sunitinib in patients with advanced renal cell carcinoma.

Therapy adjustments in MDR HIV are explored by Dr Sension.

Optimized background regimens are highlighted in the treatment approach for MDR HIV by Michael Sension, MD.

Patients with complex chronic disease can be grouped by varying propensity for health care continuity patterns, which could be harnessed to personalize health care utilization interventions.

The FDA approved an expanded indication for abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, HER2-negative, node-positive, early breast cancer that is at a high risk of recurrence.

The EASIX scoring system should not be used to predict outcomes following allogeneic stem cell transplantation (alloSCT) in patients with myelofibrosis.

This article examines the effect of a transplant case management program on clinical outcomes following transplant surgery.

Results for the STELLAR trial, presented at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology, hit nearly every mark: patients taking sotatercept improved their performance on a 6-minute walk test by 40.8 meters, which was the primary end point, and achieved 8 of 9 secondary end points.

Drs Michos and Baum provide payer considerations regarding HoFH treatment pathways.

Considerations for authorization documentation in HoFH treatment are discussed.

Pegcetacoplan was approved by the FDA to treat geographic atrophy (GA), providing a treatment option for patients who previously had none, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.

The researchers used Paraphase on more than 400 samples of spinal muscular atrophy (SMA) comprising 5 ethnicities.

The risk of death among people with primary myelofibrosis (PMF) dropped by 53% after ruxolitinib’s introduction, the study found, although the data also suggested only 8.5% of patients were prescribed the drug.

Results from the CLEAR Outcomes trial were presented today at the 72nd American College of Cardiology (ACC) Scientific Session Together With the World Congress of Cardiology. Plans for a broader label are in the works.

Dr Haumschild leads a discussion highlighting goals of therapy and social determinants of health affecting MDR HIV diagnosis and treatment.

Veeral Sheth, MD, MBA, FACS discusses re-treatment in patients with wet AMD who have previously failed an anti-VEGF therapy.

A panel of experts explore burdens impacting patients diagnosed with MDR HIV.

Dr Coney expands on the role and impact of approved label dosing of faricimab.

Manmeet Ahluwalia, MD, MBA, Miami Cancer Institute, discussed efforts being taken by his organization’s Center for Equity in Cancer Care & Research to address disparities in clinical trial enrollment of minority patients in the United States.

The 72nd American College of Cardiology Scientific Session Together With the World Congress of Cardiology (ACC.23/WCC), runs from Saturday to Monday in New Orleans, Louisiana.

Starting immunotherapy prior to surgical resection led to better outcomes vs standard, adjuvant-only immunotherapy in a phase 2 trial of patients with advanced melanoma.

Idecabtagene vicleucel (ide-cel) reduced the risk of disease progression or death by 51% in patients with triple-class–exposed relapsed or refractory multiple myeloma (R/R MM).